Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $10.80.
Several research firms have weighed in on RGLS. Canaccord Genuity Group raised their target price on shares of Regulus Therapeutics from $11.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, June 25th. StockNews.com upgraded Regulus Therapeutics to a “sell” rating in a research report on Tuesday, September 17th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Regulus Therapeutics in a research note on Tuesday. Finally, Oppenheimer reissued an “outperform” rating and set a $7.00 price target on shares of Regulus Therapeutics in a research report on Wednesday, August 14th.
Read Our Latest Stock Analysis on Regulus Therapeutics
Institutional Inflows and Outflows
Regulus Therapeutics Price Performance
Shares of NASDAQ:RGLS opened at $1.55 on Friday. The firm has a market capitalization of $101.47 million, a price-to-earnings ratio of -1.06 and a beta of 1.62. The business’s 50 day simple moving average is $1.61 and its 200-day simple moving average is $2.00. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.
Regulus Therapeutics (NASDAQ:RGLS – Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, meeting the consensus estimate of ($0.17). On average, equities analysts anticipate that Regulus Therapeutics will post -0.8 earnings per share for the current year.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Read More
- Five stocks we like better than Regulus Therapeutics
- How to Invest in Biotech Stocks
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- How to Plot Fibonacci Price Inflection Levels
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.